Share this article on:

Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients

Gayà, Antonia,d; Esteve, Annab; Casabona, Jordib; McCarthy, Jeanette Jc; Martorell, Jaumed; Schulz, Thomas Fe; Whitby, Deniseffor the EURO-SHAKS working group

Basic Science

Background: In 1994 human herpesvirus 8 (HHV-8) was identified as the causative agent of Kaposi's sarcoma (KS). Moreover, the crucial role of HLA molecules in determining susceptibility to several infections was recognized.

Objectives: To evaluate the influence of HLA-DRB1 polymorphism in KS susceptibility among HHV-8 infected AIDS patients.

Design: A matched case–control study was designed to identify possible biological and environmental risk factors for HIV associated KS. Cases were defined as any AIDS patient with a clinical diagnosis of KS and controls as any AIDS patient with an indicative disease other than KS or with CD4 cells counts < 200 × 106 cells/l, diagnosed at ± 4 months after case diagnosis. Each case was matched with two controls by sex, age and transmission category.

Methods: HHV-8 serostatus was determined by immunofluorescence assay for the latency associated antigen encoded by Orf73, ELISA for Orf73 and ELISA for the lytic antigen Orf65. DRB1 typing was carried out with a commercially available PCR–sequence specific primer assay.

Results: Comparison of marker frequencies in HHV-8 infected AIDS patients with or without KS showed a positive association between KS and HLA-DRB1 alleles containing phenylalanine at position 13 [odds ratio (OR), 2.24; P = 0.016]. A negative association was observed when the residue at the same position was glycine (OR, 0.16; P = 0.009).

Conclusion: These observations suggest a possible role for HLA-DRB1 in the development of KS in HHV-8 infected individuals with HIV co-infection. Progression to KS in HHV-8 infected AIDS patients may also depend on host factors controlling the immune response.

From the aFundació Banc de Sang i Teixits, Palma de Mallorca, bCentre d'Estudis Epidemiològics sobre l'HIV/sida de Catalunya (CEESCAT). Hospital Universitari Germans Trias i Pujol, Badalona, Spain, cSan Diego State University, San Diego, California, USA, dServei d'Immunologia, IDIBAPS, Hospital Clínic, Barcelona, Spain, the eDepartment of Medical Microbiology and Genitourinary Medicine. University of Liverpool, and fThe Institute of Cancer Research, London, UK. *See Appendix.

Correspondence to A. Gayà, Fundació Banc de Sang i Teixits de les Illes Balears, Rosselló i Caçador, 20, 07004 Palma de Mallorca, Spain.

Received: 16 September 2002; revised: 2 May 2003; accepted: 13 May 2003.

Back to Top | Article Outline


From the beginning of the AIDS epidemic, Kaposi's sarcoma (KS) has been one of the defining conditions of the disease [1]. Until the introduction of highly active antiretroviral therapy (HAART), it was the most common malignancy associated with HIV-1 infection [2]. The high prevalence of HIV-related KS among men who have sex with men (MSM) compared to other groups of HIV patients infected by non-sexual routes, suggested that a sexually transmitted infectious agent could be responsible for KS [3]. In 1994 a new herpes virus, Kaposi sarcoma associated herpesvirus/human herpes virus 8 (HHV-8) was identified in HIV-related KS tissue [4]. HHV-8 has since been shown to be the causative agent of KS [5–9]. Cohort studies indicate that among HIV infected MSM, about half of those infected with HHV-8 develop KS between 5 and 10 years after contracting HHV-8 [10,11]. HHV-8 infection, once acquired, develops as a life-long chronic infection like other herpesviruses such as Epstein–Barr virus. In most cases, this infection is controlled through life by immune surveillance; however in a minority of individuals infection is not effectively controlled, leading to a proliferation of infected cells and, eventually, to malignancy. Thus, in addition to immunosuppression [12], host-related factors may also play a role in KS pathogenesis.

Because of the crucial role played by HLA in the development of the immune response, HLA could be one potential host-related cofactor. Binding of peptides from the infectious pathogens to HLA proteins is the first step in initiation of the host-specific immune response. The peptide-binding groove on HLA molecules contains pockets which are binding sites for anchor residues in peptides. Different HLA molecules have slightly different peptide-binding clefts and accordingly bind and present different sets of peptides to T cells. The differences are determined by the polymorphic residues of HLA molecules. Polymorphic amino acid residues located in the pockets have a dramatic effect on the spectrum of peptides that are bound by a particular HLA molecule. In accordance, immune response against a pathogen will vary among individuals.

Variability in HLA has been shown to influence response to infection with human pathogens and disease outcome. Strong evidence for HLA associations have been reported for malaria, hepatitis B, HTLV-I and HIV [13–16]. The association between HLA and classic KS has also been analysed and an increased incidence of HLA-DR5 has been reported [17,18]. However, when HLA typing was carried out by molecular techniques, this could not be confirmed [19]. Several studies have reported significant associations between HLA genotype and AIDS-related KS [20–25]. In these studies, a positive association with DR5 has been described when population controls were used as the comparison group. When HIV-1 positive disease-free individuals were used as the control group, Mann et al. [21] found a positive association with DR1, DQ1, B35 and Cw4. An association between DR1 and AIDS-related KS was also described by Klein et al. [25]. However, in these studies, the HHV-8 infection status of the controls was unknown.

The aim of this paper is to present the results of the HLA typing derived from a European case–control study, comparing patients with and without KS, and also to compare the HLA subtypes between HHV-8 positive and HHV-8 negative participants.

Back to Top | Article Outline

Materials and methods

Human subjects

In 1992 a multi-centre matched case–control study funded by the European Union (EURO-SHAKS: European Study on HIV Associated Kaposi's Sarcoma, DG XII), was designed to identify possible biological, behavioural and environmental risk factors for HIV associated KS. Participant countries were Spain, Belgium, UK, Italy and Greece. Cases were defined as any AIDS patient with a clinical diagnosis of KS and controls as any AIDS patient with an indicative disease other than KS or with CD4 cells counts < 200 × 106 cells/l, diagnosed at ± 4 months after case diagnosis. Each case was matched with two controls by sex, age and transmission category [26,27]. After informed consent, each study participant was interviewed for socio-demographic and behavioural data, and sera, blood clots, plasma and whole blood were obtained and stored at −20°C for later analysis. By the end of 1998, a total of 483 patients (161 triplets) had been recruited. In 1998, sera samples from both cases and controls were tested for HHV-8.

Because HLA typing was performed only among participants from Spain, for the purpose of this research, patients from other countries have been excluded from the analysis. Moreover, to decrease the number of potential confounders, only Caucasian MSM were included. Out of 354 Spanish participants, 308 fulfilled the above mentioned inclusion criteria. In addition, three patients were excluded from the study because of insufficient biological sample for HHV-8 analysis. Therefore, the study group consisted of 305 individuals: 103 (n1) cases with KS and 202 (n0) controls with AIDS (a CD4 cell count < 200 × 106 cells/l was accepted as AIDS criteria [28]) but without KS. Cases and controls were compared for both mean age (38.7 and 38.3 years, respectively) and CD4 cell count at entry (differences were not significant). Additionally, KS was the first indicative disease in 80% of the cases.

Back to Top | Article Outline

Laboratory methods

Sera were analysed for HHV-8 infection using three different assays: immunofluorescence assay for the latency associated antigen (LANA) encoded by Orf73, ELISA for Orf73 and ELISA for the lytic antigen Orf65 as described previously [6,8,12]. A sample was considered to be HHV-8 positive if reactive to any of the three assays.

Back to Top | Article Outline

DNA isolation and HLA typing

Peripheral blood samples were obtained and subjected to isolation of genomic DNA with a QIAamp blood kit (Qiagen, Hilden, Germany). HLA-DRB1* typing was performed by PCR with sequence-specific primers according to manufacturer's recommendations (Dynal3, Oslo, Norway).

Back to Top | Article Outline

Statistical analysis

Patients’ ages and CD4 cell counts were compared by Student's t test and the Mann–Whitney U test, respectively. Because the study population for this analysis comprised only homosexual men and no differences between cases and controls were found regarding age and CD4 cell count, an unmatched analysis was performed. HLA class II marker frequencies were analysed as described previously [29,30]. The odds ratio (OR) and its 95% confidence interval (CI) were computed to estimate the degree of association between the presence of the allele and the disease; when any observed value was equal to 0, Haldane's modification of Woolf's method was used [30]. The significance of the OR deviation from unity was estimated by Fisher's exact test with two-tailed P-value. The corrected P-value is denoted by pc; the correction factor was 14 (given in parentheses), i.e., the number of alleles tested.

Back to Top | Article Outline


The overall HHV-8 seroprevalence was 70.8% (216/305), with 91.3% (94/103) and 60.4% (122/202) respectively for cases and controls (P < 0.001). There are no published data on susceptibility to HHV-8 infection in relation to HLA Class II molecules. To assess whether HHV-8 infected and non-infected patients were homogeneous for HLA Class II alleles, we first compared the results of HLA-DRB1 typing according to HHV-8 antibody status (Table 1). Slight differences in the frequency of some alleles were observed, but after correction these differences were not statistically significant. Although with our study design risk of infection cannot be estimated, the results could suggest that no HLA-DRB1 allele is a risk or protective factor for HHV-8 infection.

Table 1

Table 1

Given that HHV-8 is a necessary factor for KS development [5–9], for the purpose of assessing the potential role of HLA alleles in KS development we only used participants who were HHV-8 infected. Marker frequencies of HLA-DRB1 between KS AIDS patients (94 cases) and non-KS AIDS patients (122 controls) were compared among HHV-8 infected persons (Table 1). Several alleles exhibited a trend towards allelic frequency differences between the KS and control groups, with uncorrected P values < 0.05. Thus, the frequency of DRB1*01 was higher in KS patients than in the control group (DRB1*01: OR, 2.15; 95% CI, 1.13–4.08; P = 0.023; pc(14) = 0.322), suggesting that this allele could constitute a risk factor for KS development in HHV-8/HIV co-infected AIDS patients, in agreement with previously published data [21,25]. On the other hand, some alleles showed an inverse relationship, being more frequent among the AIDS patients who did not develop KS. There were two alleles with an OR < 0.3: DRB1*12 (OR, 0.12; 95% CI, 0.02–0.96) and DRB1*08 (OR, 0.25; 95% CI, 0.03–2.19). However, only DRB1*12 was statistically significant (P = 0.025), and this significance disappeared after correction for the number of comparisons [pc(14) = 0.350].

Interestingly, comparison of the amino acid sequence of the different DRB1 alleles shows that almost all the DRB1*08 and DRB1*12 alleles share an amino acid residue, glycine (G), at position 13 of the β chain. The other DRB1* alleles contain several other amino acids at position 13, but glycine seems to be restricted to DRB1*08 and DRB1*12. From analysis of the sequence we could not find any other polymorphic position that was common to DRB1*08 and DRB1*12 but was not present in all the other alleles. Comparison of the frequency of glycine's presence at position 13 among HHV-8 positive cases and controls shows an increased statistically significant difference (OR, 0.16; 95% CI, 0.03–0.70; P = 0.009).

Several reports describe susceptibility to KS pathogenesis associated with DR1 in AIDS patients [21,25]. Although in our group of patients the risk associated with the presence of DRB1*01 was not statistically significant, an increased frequency of this allele was observed in KS patients in comparison with the control group (Table 1). This fact is especially relevant taking into account that the amino acid at position 13 in the β chain of DRB1*01 alleles, with the exception of DRB1*0103, is phenylalanine (F). The presence of F at position 13 of the β chain shows a statistically significant relationship with the development of KS in AIDS patients (OR, 2.24; 95% CI, 1.19–4.20; P = 0.016). In this analysis, those patients displaying DRB*09 and DRB*10, alleles which also contained F at position 13 were included although they were very uncommon.

However, this comparison could possibly be influenced by the fact that the comparison group used also included those patients who were G13 and, as shown above, this residue's behaviour was the opposite to that of F13. Therefore, we reanalysed the sample (Table 2) by comparing cases against HHV-8 infected controls who typed as F13 with those who were neither F13 nor G13 and we found that frequency of F13 was still higher in cases (OR, 2.1; 95% CI, 1.09–3.97; P = 0.035). The same comparison was performed for the presence of G13, and similar results were found (OR, 0.20; 95% CI, 0.04–0.92; P = 0.029). Finally, we also analysed the effect of G13 and F13 polymorphism if cases were compared against controls, irrespective of serostatus. In this case, the differences were also statistically significant (data not shown).

Table 2

Table 2

Back to Top | Article Outline


One mechanism to account for HLA associations with susceptibility or resistance to KS pathogenesis is varying efficiency of HHV-8 antigen presentation by different HLA molecules. The different frequencies of several alleles could be interpreted in the context of the immune response against this infectious agent. It has been demonstrated that the natural polymorphism of HLA molecules can influence both the specificity and affinity of peptide binding. Therefore, it is possible that certain HLA molecules bind and present HHV-8 antigens more efficiently than others. Our data show that resistance to KS development was independently associated with a precise amino acid at position 13 of the DRβ chain. In this case, alleles DRB1*08 and DRB1*12 would have the capacity to present a certain peptide which would lead the immune response to control the pathogenic effect of HHV-8, thus suggesting that anti-HHV-8 class II restricted CD4 cell count may play an important role in protecting against viral challenge. In fact, strong T-helper cell responses to an HIV-1 p24 antigen have been correlated with a reduced virus load and risk of HIV-1 disease progression [31] and are likely to contribute to a sustained potent cytolytic CD8 response.

Position 13 of the β chain is especially significant because, together with amino acids at positions 70 and 71, it lines a pocket, named pocket 4 [32], which determines the binding characteristics of peptides to the cleft. Thus, we could relate the potential protective action of DRB1*08 and DRB1*12 more precisely to a specific sequence common to these alleles which is directly involved in determining the specificity of the peptide bound by the HLA molecule. Although this residue is also found in some other alleles, such as DRB1*1105 and DRB1*1404, these are extremely infrequent in Caucasians [33], and thus the possibility that they were present in our sample is negligible.

More interestingly, the side chain of F is especially large as it includes an aromatic group. This is in contrast with G, the amino acid present in DRB1*08/*12 alleles, which display the smallest side chain among the different amino acids. Thus, the size of the side chain of the amino acid at position 13 could determine that the peptide presented by the G13 containing DRB1*08/12 alleles, capable of eliciting a protective immune response, would not be presented by DRB1*01 alleles at all. An alternative explanation could be that DRB1*01 is responsible for the presentation of another peptide which could select a defective immune response and thus favour the development of KS.

Our results are constrained by some study design limitations that deserve further comment. Firstly, by studying patients participating in a case–control study, we are analysing disease outcomes at a given point of time and therefore we cannot assess either risk of HHV-8 infection or rate of KS development. Secondly, the original matching design scheme was not maintained in the analysis, and some confounders may have been introduced. Nevertheless, although no biological marker for disease stage was used as a matching factor, most of the non-KS patients were included because of a CD4 cell count < 200 × 106 cells/l inclusion criterion, and therefore both cases and controls were at a quite advanced stage of the infection. In this analysis we included only Spanish Caucasian men who acquired HIV infection through homosexual sex, so there was no need to match for these factors. The fact that all studied patients were included between 1994 and 1996, before HAART was widely introduced in Spain, ensures that the observed effect of HAART, decreasing the KS incidence, is not a confounder in our study [34,35]. Finally, since the ages of both KS and non-KS patients were similar, we believe that no confounders have affected the observed differences.

The HLA-DRB1 gene shows a close association with DRB3-5 loci as well as with HLA-DQ genes and the different alleles are found in linkage disequilibrium. Although we did not analyse these other genes, we believe it improbable that the observed association could be due to the effect of genes other than DRB1. Concerning the DRB3-5 loci, whereas the DRB1*01 or DRB1*08 haplotypes do not contain these genes, the DRB1*12 haplotypes contain the DRB3 gene. In addition, association with a common DQ allelic variant is quite unlikely, since DRB1*08 and DRB1*12 are usually linked to different DQ alleles.

In summary, we cannot conclude on the role of HLA in facilitating or protecting against HHV-8 infection; however, our findings of a statistically significant association between certain amino acids at position 13 of the β chain of DR molecules between HHV-8 infected patients with and without KS, suggest a relevant role of the immune response in the interaction of this agent and KS pathogenesis. To elucidate better the role of these molecules on HHV-8 acquisition and its interrelation with KS development, these associations should be confirmed in subsequent independent studies and, preferably, of longitudinal design.

Back to Top | Article Outline


We would like to acknowledge the technical assistance in DNA isolation and HLA typing of F. Isart, B. Suarez, V. Fabregat, M.T. Arias, and M. Massó, and the field work of R. Muñoz.

Sponsorship: Supported in part by DG XII of the European Commission (EURO-SHAKS), Fondo de Investigaciones Sanitarias (FIS) and Laboratories MSD (Madrid, Spain). We also acknowledge the support provided by CIRIT and the Health Department (Generalitat de Catalunya, Barcelona, Spain) and the U.K. Medical Research Council.

Back to Top | Article Outline


1. Centers for Disease Control (United States). Revision of the CDC Surveillance Case Definition for Acquired Immunodeficiency Syndrome. MMWR 1987, 36:(Suppl 1S):3S–15S.
2. Haverkos HW, Drotman PD. Prevalence of Kaposi's sarcoma among patients with AIDS. N Engl J Med 1985, 312:1518–1521.
3. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990, 335:123–128.
4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266: 1865–1869.
5. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff CH, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995, 346:799–802.
6. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff, CH, Rainbow L, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996, 348:1133–1138.
7. Gao SJ, Kinsgley LA, Hoover DR, Spira TJ, Rinaldo CR, Saah AJ, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated Herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996, 335:233–241.
8. Renwick N, Halaby T, Weverling GJ, Dukers NHTM, Simpson GR, Coutinho RA, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998, 12:2481–2488.
9. Dukers NH, Renwick N, Prins M, Geskus RB, Schulz TF, Weverling GJ, et al. Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol 2000, 151:213–224.
10. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998, 338:948–954.
11. Jacobson LP, Jenkins FJ, Springer G, Munoz A, Shah KV, Phair J, et al. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis 2000, 181:1940–1949.
12. Gambús G, Bourboulia D, Esteve A, Lahoz R, Rodríguez C, Bolao F, et al. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS 2001, 15:1167–1174.
13. Thursz B, Kwiatkowski M, Allsop CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995, 332:1065–1069.
14. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991, 352:595–600.
15. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999, 96: 3848–38453.
16. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996, 2:405–411.
17. Contu L, Cerimele D, Pintus A, Cottoni F, La Nasa G. HLA and Kaposi's sarcoma in Sardinia. Tissue Antigens 1984, 23: 240–245.
18. Papasteriades C, Kaloterakis A, Filiotou A, Economidou J, Nicolis G, Trichopoulos D, et al. Histocompatibility antigens HLA-A, -B, -DR in Greek patients with Kaposi's sarcoma. Tissue Antigens 1984, 24:313–315.
19. Strichman-Almashanu L, Weltfriend S, Gideoni O, Friedman-Birnbaum R, Pollack S. No significant association between HLA antigens and classic Kaposi sarcoma: molecular analysis of 49 Jewish patients. J Clin Immunol 1995, 15:205–209.
20. Scorza-Smeraldi R, Fabio G, Lazzarin A, Eisera NB, Moroni M, Zanussi C. HLA associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet 1986, 2:1187–1189.
21. Mann D, O'Donnell M, Blattner W, Goederr J. Analysis of HLA alloantigen frequencies in patients with HIV-1 related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1990, 3:S51–S5.
22. Friedman-Kien, Alvin E, Laubenstein LJ, Rubenstein P, Buimovici-Klein E, Marmor M, et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982, 96:693–700.
23. Pollack MS, Safal B, Dupont B. HLA-DR5 and HLA-DR2 are susceptibility factors for acquired immunodeficiency syndrome with Kaposi's sarcoma in different ethnic subpopulations. Dis Markers 1983, 1:135.
24. Prince HE, Schroff RW, Ayoub G, Han S, Gottlieb MS, Fahey JL. HLA studies in acquired immunodeficiency syndrome patients with Kaposi's sarcoma. J Clin Immunol 1984, 4:242.
25. Klein MR, Keet IP, D'Amaro J, Bende RJ, Hekman A, Mesman B, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994, 169:1244–1249.
26. Centre d'Estudis Epidemiològics sobre la Sida de Catalunya (CEESCAT) (Spain). EURO-SHAKS: European Study on HIV Associated Kaposi's Sarcoma. Workshop Barcelona, June 1998. Barcelona: Generalitat de Catalunya, Departament de Sanitat i Seguretat Social, 1998. Document Tècnic CEESCAT, 8.
27. Casabona J, Gambús G, Vall M, Rodés A. Risk factors for AIDS associated Kaposi's sarcoma. Pathol Oncol Res 1997, 3:74–77.
28. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(no. RR–17).
29. Svejgaard A, Ryder LP. HLA and disease associations: Detecting the strongest association. Tissue Antigens 1994, 43:18–27.
30. Tiwari JL, Terasaki PI. HLA and Disease Associations. New York: Springer-Verlag; 1985.
31. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science 1997, 278: 447–1450.
32. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368:215–221.
33. Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. New York: Oxford University Press; 1992.
34. Buchbinder S, Holmberg S, Scheer S. Effect of highly active antiretroviral therapy on the incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 1999, (Suppl 1):S23–S6.
35. Sparano JA, Anand K, Desai J, Mitnick RJ, Kalkut GE. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Defic Syndr 1999, 21:S18–S22.
Back to Top | Article Outline


EURO-SHAKS working group

Ma Mercè Alsina Gibert, Elisabeth Buira (Hospital Clínic i Provincial de Barcelona), Cristina Tural (Hospital Universitari Germans Trias i Pujol), Imma Ocaña, Isabel Ruiz, Marjori Díaz (Hospital General Universitari Vall d'Hebron), Montserrat Fuster, Lali Baselga, Marta Alegre (Hospital de la Santa Creu i Sant Pau), Ferran Bolao, Elena Ferrer, Daniel Podzamczer (Hospital de Bellvitge), Rafael Rubio (Hospital XII de Octubre), José Luís López Colomes (Hospital del Mar), Martí Vall (Direcció d'Atenció Primària Ciutat Vella), José M Gatell (Hospital Clínic i Provincial de Barcelona), Bonaventura Clotet (Hospital Universitari Germans Trias i Pujol), Josep Cadafalch (Hospital de la Santa Creu i Sant Pau).


HLA-DRB1; human herpesvirus 8; HIV; antigen presentation; immune response

© 2004 Lippincott Williams & Wilkins, Inc.